Table 1.

Characteristics of Included Studies^a

Reference,first author	Number of patients	Age, years	Diabetes duration, years	% CSII	Baseline HbA1c	CGM frequency	SMBG frequency
Chase24b	11	13.4 ± 13.6	6.2 ± 9.9	54.6%	9.5 ± 0.95	72 h/5 days	Not reported
Chico33b	75	38.7 ± 11	19 ± 11	0%	8.2 ± 1.5	72 h/3 months	Not reported
Ludvigsson25b	32	12.5 ± 3.3	7.0 ± 3.9	51.9%	7.7 ± 0.95	72 h/2 weeks	≥2x/day + 7-point SMBG/week
Tanenberg26b	109	44.3 ± 11.4	19.9 ± 9.9	45.8%	9.1 ± 1.1	72 h/3 months	≥4x/day
Deiss11c	162	26.8 ± 13.6	Not reported	48.1%	9.6 ± 1.1	Continuous or 72 h/2 weeks	Not reported
Deiss27b	30	11.4 ± 13.6	2.2 ± 9.9	Not reported	8.1 ± 1.1	72 h/3 months	Not reported
Lagarde28b	27	11.4 ± 13.6	4.4 ± 9.9	70.4%	7.85 ± 1.3	72 h/2 months	≥4x/day + 2 AM/week
Yates29b	36	14.4 ± 13.6	Not reported	47%	7.9 ± 0.85	Eight 72 h periods	4–6x/day
Hirsch14c	138	33.1 ± 15.5	18.7 ± 11.6	100%	8.45 ± 0.7	Continuous	Not reported
JDRF6c	322	24.4 ± 5.5	12.5 ± 6	79.7%	7.85 ± 0.6	Continuous	≥4x/day
Cosson30b	41	53.8 ± 13.6	15.9 ± 9.9	11.1%	9.05 ± 1.05	Two 48 h periods	Not reported
O’Connell31c	62	23.2 ± 8.4	10.2 ± 7.4	100%	8.4 ± 1.65	Continuous	≥4x/day
Peyrot36c	28	47.2 ± 13.2	25 ± 12.6	100%	8.6 ± 1.0	Continuous	Not reported
Raccah32c	115	28.5 ± 15.9	11.8 ± 8.9	100%	9.2 ± 1.24	Continuous	≥3x/day

^aContinuous, wearing the device ≥6 days/week or 70% of the time; % CSII, percentage of patients using continuous subcutaneous insulin infusion.

^bRetrospective CGM.

^cReal-time CGM.